Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

Cancer Immunology, Immunotherapy

Volumn 65, Issue 5, 2016, Pages 563-573

  Coleman, Hannah N ^a   Greenfield, William W ^a   Stratton, Shawna L ^a   Vaughn, Rita ^a   Kieber, Alexander ^a   Moerman Herzog, Andrea M ^a   Spencer, Horace J ^a   Hitt, Wilbur C ^a   Quick, Charles Matthew ^a   Hutchins, Laura F ^a   Mackintosh, Samuel G ^a   Edmondson, Ricky D ^a,b   Erickson, Stephen W ^a   Nakagawa, Mayumi ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cervical intraepithelial neoplasia; Clinical trial; HPV; T cells; Therapeutic vaccine; Viral load

Indexed keywords

CXCL9 CHEMOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR BETA SUBUNIT; PEPTIDE VACCINE; PLATELET DERIVED GROWTH FACTOR B; RANTES; VASCULOTROPIN; WART VIRUS VACCINE; CYTOKINE; PROTEOME; SUBUNIT VACCINE;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MEGADOSE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INJECTION SITE REACTION; LOW DRUG DOSE; PAPILLOMAVIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REGULATORY T LYMPHOCYTE; TH1 CELL; VACCINATION; VIRUS DETECTION; VIRUS ENTRY; VIRUS LOAD; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; PROCEDURES; TANDEM MASS SPECTROMETRY; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADULT; CHROMATOGRAPHY, LIQUID; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROTEOME; PROTEOMICS; T-LYMPHOCYTES, REGULATORY; TANDEM MASS SPECTROMETRY; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, SUBUNIT; VIRAL LOAD; YOUNG ADULT;

EID: 84961192185     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1821-x     Document Type: Article

References (35)

1. Cancer IAfRo (2012) Globocan 2012 cancer fact sheet
2. Chaturvedi AK (2010) Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 46(4 Suppl):S20–S26
3. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL (2011) Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 53(Suppl 1):S12–S21
4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3):621–632
5. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN (2015) Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines. Clin Vaccine Immunol 22(7):679–687
6. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386(10008):2078–2088
7. Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M (2013) Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine 31(49):5806–5813
8. Clifton MM, Johnson SM, Roberson PK, Kincannon J, Horn TD (2003) Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol 20(3):268–271
9. Horn TD, Johnson SM, Helm RM, Roberson PK (2005) Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol 141(5):589–594
10. Johnson SM, Horn TD (2004) Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy. J Drugs Dermatol 3(3):263–265
11. Johnson SM, Roberson PK, Horn TD (2001) Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol 137(4):451–455
12. Phillips RC, Ruhl TS, Pfenninger JL, Garber MR (2000) Treatment of warts with Candida antigen injection. Arch Dermatol 136(10):1274–1275
13. Maronn M, Salm C, Lyon V, Galbraith S (2008) One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol 25(2):189–192
14. Nakagawa M, Coleman HN, Wang X, Daniels J, Sikes J, Nagarajan UM (2014) IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine 65(2):202–209
15. Bruinsma FJ, Quinn MA (2011) The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 118(9):1031–1041
16. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7):743–753
17. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN, Mercado M, Moerman-Herzog AM, Spencer HJ, Andrews-Collins NR, Hitt WC, Low GM, Manning NA, McKelvey SS, Smith D, Smith MV, Phillips AM, Quick CM, Jeffus SK, Hutchins LF, Nakagawa M (2015) A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology 4(10):e1031439
18. Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, Herrero R, Hildesheim A, Wacholder S, Scibior-Bentkowska D, Burk RD, Lorincz AT (2013) Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 132(6):1412–1422
19. Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M, Zerbini M (2007) Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 106(3):549–557
20. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV (2003) Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 112(1–2):23–33
21. Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362
22. Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, Akira S, Wiegand M, Hochrein H, O’Keeffe M, Mann M (2010) Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32(2):279–289
23. Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75(17):4646–4658
24. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3(1):1–25
25. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847
26. Carcopino X, Bolger N, Henry M, Mancini J, Boubli L, Olive D, Cleary S, Prendiville W, Tamalet C (2011) Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology. J Med Virol 83(4):637–643
27. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102(7):1129–1136
28. 2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein-coupled receptor 75. Br J Pharmacol 149(5):490–497
29. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347(6294):669–671
30. Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, Cookenham T, Roberts AD, Woodland DL (2008) The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29(1):101–113
31. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176(2):587–592
32. Lin CL, Suri RM, Rahdon RA, Austyn JM, Roake JA (1998) Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation. Eur J Immunol 28(12):4114–4122
33. Romagnani S (2002) Cytokines and chemoattractants in allergic inflammation. Mol Immunol 38(12–13):881–885
34. Maghazachi AA, Al-Aoukaty A, Schall TJ (1996) CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol 26(2):315–319
35. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7(2):285–289